Irinotecán Qilu (Irinotecan Hydrochloride Trihydrate)

Irinotecan is converted to its active metabolite SN‑38, which inhibits the enzyme topoisomerase I. This inhibition prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and ultimately causing cancer cell death.

The dosing regimen for Irinotecán Qilu is individualized by the prescribing oncologist based on factors such as cancer type, stage, patient weight, and overall health. The prescriber determines the appropriate dose and schedule for each patient.

Safety data for Irinotecán Qilu in pregnancy and lactation are limited. It is generally contraindicated in pregnant or nursing women because of potential risks to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To order Irinotecán Qilu, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinotecán Qilu belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines or oxaliplatin. It is often combined with other agents to enhance efficacy. Compared with alternatives, it provides a valuable option for patients who may not tolerate or have progressed on other regimens.

Irinotecán Qilu should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Use aseptic technique when preparing the injection, and discard any solution that appears discolored or contains particles.

The medication is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a set period of time as directed by the treatment protocol, and may be given alone or in combination with other chemotherapy agents.

The most serious risks include severe neutropenia leading to infection, life‑threatening diarrhea or colitis, hepatic toxicity, and rare allergic reactions such as anaphylaxis. Patients should be closely monitored for signs of infection, gastrointestinal complications, and liver function abnormalities.

Irinotecán Qilu is contraindicated in patients with known hypersensitivity to irinotecan or any of its excipients, in those with active severe infections, and in individuals with recent bowel obstruction. Caution is also advised for patients with significant liver or kidney impairment.